Vyndaqel/Vyndamax
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Vyndaqel/Vyndamax in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Vyndaqel/Vyndamax.
47
Global Revenue Ranking
Recent articles on PMLiVE featuring Vyndaqel/Vyndamax
The company said it will be proceeding with regulatory filings for the therapy later this year
The liver-targeted antisense therapy is in phase 3 trials for the treatment of transthyretin amyloidosis, a systemic, progressive and fatal condition
Strong third-quarter revenues of $24.1bn lifted by sales of its BioNTech-partnered COVID-19 vaccine Comirnaty see Pfizer raise its 2021 revenue guidance to $82bn
COVID-19 vaccine generated $7.8bn in the second quarter of 2021 alone
Five individuals we think will have a key role to play in the sector in 2020 and beyond
Faces a challenging period as big brands experience a slowdown
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology